Moderna’s phase 3 trial demonstrates its mRNA flu-vaccine recipients age 50 and older were roughly one-quarter less likely to develop confirmed influenza illness than counterparts receiving standard-dose conventional flu-vaccines—though effectiveness relative to enhanced high-dose/adjuvanted vaccines often recommended for adults age 65 and older remains unknown, as made clear by one of Dr. Prasad’s final stands before his ousting as director of CBER. | Leroux-Roels, N Engl J Med 2026
